Shawn E McCandless MD
Clinical Biochemical Genetics, Clinical Genetics, Medical Biochemical Genetics
Professor, Department of Pediatrics, University of Colorado Anschutz Medical Campus
Join to View Full Profile
13123 E 16th AveAurora, CO 80045
Phone+1 848-777-1234
Fax+1 720-777-7321
Dr. McCandless is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Shawn McCandless is a medical geneticist in Aurora, CO and is affiliated with Children's Hospital Colorado. He received his medical degree from Lewis Katz School of Medicine at Temple University and has been in practice 29 years. He specializes in clinical biochemical genetics, clinical genetics, and medical biochemical genetics and is experienced in prader-willi syndrome, mitochondrial diseases, inborn errors of metabolism, intellectual disability, and neonatal screening.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Medical Biochemical Genetics, 2003 - 2005- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Medical Genetics and Genomics, 1996 - 1999
University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 1988 - 1991
Lewis Katz School of Medicine at Temple UniversityClass of 1988
Certifications & Licensure
CO State Medical License 2018 - 2025
WY State Medical License 2021 - 2025
OH State Medical License 1998 - 2018
NC State Medical License 1999 - 2004
WI State Medical License 1989 - 1999
American Board of Medical Genetics and Genomics Clinical Biochemical Genetics- American Board of Medical Genetics and Genomics Clinical Genetics and Genomics
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Longitudinal Study of Urea Cycle Disorders Start of enrollment: 2006 Feb 01
- Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Start of enrollment: 2014 Sep 01
- A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders Start of enrollment: 2014 Dec 31
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis.Johan L K Van Hove, Marisa W Friederich, Daniella H Hock, David A Stroud, Nikeisha J Caruana
Mitochondrion. 2024-09-01 - 1 citationsBehavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.Theresa V Strong, Jennifer L Miller, Shawn E McCandless, Evelien Gevers, Jack A Yanovski
Journal of Neurodevelopmental Disorders. 2024-04-26 - 4 citationsNeuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria.Mitzie L Grant, Elaina R Jurecki, Shawn E McCandless, Stephen M Stahl, Deborah A Bilder
The Journal of Pediatrics. 2023-09-01
Press Mentions
University of Colorado Anschutz Medical Campus Named ‘Rare Disease Center of Excellence’February 8th, 2022- Aardvark Therapeutics Announces FDA Orphan Drug Designation Granted to ARD-101, a Novel Drug Candidate for Prader-Willi SyndromeJune 24th, 2023
Professional Memberships
- Member
- American College of Medical Genetics and GenomicsFellow
- Society for Inherited Metabolic DisordersMember
- American Society of Human GeneticsMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
